Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hangzhou Songyin Biomedical Science And Technology Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is assigned to 1 distinct examiner, THOMAS J VISONE. The prosecution is localized within 1 distinct art unit, which indicates a specific technical focus for the company's current pending application.
THOMAS J VISONE is the busiest examiner for this portfolio, as he is responsible for the 1 pending office action currently active. Because there is only 1 distinct examiner involved, the entire progress of the company's pending intellectual property is dependent on this individual's assessment. The concentration of the workload into 1 distinct art unit means that the company's current biotechnological innovation is being evaluated against a specific set of departmental standards.
For a practitioner, this data shows a concentrated prosecution environment with no opportunity to compare examiner behavior across different applications. The strategy for this portfolio is currently tied to the specific tendencies of 1 distinct examiner and the procedural norms of 1 distinct art unit. With only 1 pending office action, the company's immediate patent office activity is limited to this single point of contact.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VISONE, THOMAS J | 1 | 55.6% | +40.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18192674 | METHOD AND SYSTEM FOR DELIVERING NUCLEIC ACID | VISONE, THOMAS J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18192674 | METHOD AND SYSTEM FOR DELIVERING NUCLEIC ACID | VISONE, THOMAS J | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18192674 | METHOD AND SYSTEM FOR DELIVERING NUCLEIC ACID | VISONE, THOMAS J | 1672 | §103§112 | Final Rejection | — | Pending | Mar 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHangzhou Songyin Biomedical Science And Technology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Thomas J Visone has the most, with 1 of Hangzhou Songyin Biomedical Science And Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
